Sanofi discontinues clinical development of investigational JAK2 agent Fedratinib (SAR302503)
18 November 2013 | By Sanofi
Sanofi announced the decision to halt all clinical trials and cancel plans for regulatory filings with its investigational JAK2 inhibitor...